echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Medical News > Latest Medical News > The two companies have reviewed the 1 billion gastric motility drug

    The two companies have reviewed the 1 billion gastric motility drug

    • Last Update: 2021-11-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, domperidone tablets review companies have added two more, namely Shanxi Baotai Pharmaceutical and Foshan Palm Palm
    .


    Domperidone is a gastrointestinal prokinetic drug.


    Domperidone tablets are gastrointestinal prokinetic drugs, which are a strong dopamine receptor antagonist developed by Janssen, Belgium in 1978
    .


    The product directly acts on the gastrointestinal wall, can increase gastrointestinal motility and tension, promote gastric emptying, increase gastric antrum and duodenal motility, coordinate the contraction of the pylorus, and also enhance esophageal motility and lower esophageal sphincter The tension is widely used to treat nausea and vomiting


    According to data from Menet.
    com, in 2020, the total sales of domperidone in urban public hospitals, county-level public hospitals, urban community centers, township health centers (Chinese public medical institutions) and Chinese urban physical pharmacies will be close to 1 billion yuan in 2020
    .

    Sales of terminal domperidone in physical pharmacies in cities in China (unit: ten thousand yuan)

    Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern

    It is worth mentioning that domperidone tablets are the TOP1 variety in the gastrointestinal antispasmodic, anticholinergic, and gastrodynamic drug market in the physical pharmacies of cities in China.
    Its sales have long been far ahead, occupying nearly 65% ​​of the market share in 2020
    .

    2020 China's urban physical pharmacies terminal gastrointestinal antispasmodic, anticholinergic and gastrodynamic drug products TOP5

    Source: Mi Nei.
    com, China's urban physical pharmacy terminal competition pattern

    Domperidone tablets have been included in the third batch of centralized procurement, and three companies including East China Medicine (Xi'an) Bohua Pharmaceutical, Sichuan Vio Pharmaceutical, and Furen Pharmaceutical won the bid
    .

    As the domperidone tablets of Shanxi Baotai Pharmaceutical Co.
    , Ltd.
    and Foshan Palm Palm Pharmaceutical Co.
    , Ltd.
    passed the consistency evaluation, there are currently 6 companies that have passed the evaluation
    .

    Data source: Mi Neiwang database

    Note: China's urban entity pharmacy terminal competition pattern database is an enlarged version of the urban entity pharmacy database that covers 293 prefectures and cities across the country (excluding county and rural entity pharmacies), and continuously monitors all categories
    .


    The above sales are calculated based on the average retail price of the product at the terminal


    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.